Blood Res.  2022 Jun;57(2):95-100. 10.5045/br.2022.2021173.

Chronic myeloid leukemia: a type of MPN

Affiliations
  • 1Department of Medicine, Dow Medical College, Dow University of Health Sciences, Karachi, Pakistan

Abstract

This review article classifies chronic myeloid leukemia (CML) based on cytogenetic analyses and different mutations detected in CML patients. The use of advanced technologies, such as karyotyping, fluorescent in situ hybridization, and comparative genomic hybridization, has allowed us to study CML in detail and observe the different biochemical changes that occur in different CML types. This review also highlights the different types of receptor and signaling pathway mutations that occur in CML.

Keyword

Chronic myeloid leukemia; Cytogenetics; Philadelphia chromosome; Myeloproliferative neoplasms

Figure

  • Fig. 1 Translocation of the break-point cluster region (BCR) gene.

  • Fig. 2 Gene mutations detected in patients with chronic myelomono-cytic leukemia (CMML).


Reference

1. Besa EC, Grethlein SJ. 2021. Chronic myelogenous leukemia (CML): practice essentials, background, pathophysiology. Medscape;New York, NY: at https://medicine.medscape.com/article/199425-overview. Accessed September 11, 2021.
2. Shtivelman E, Lifshitz B, Gale RP, Canaani E. 1985; Fused transcript of ABL and BCR genes in chronic myelogenous leukaemia. Nature. 315:550–4. DOI: 10.1038/315550a0. PMID: 2989692.
Article
3. Swerdlow SH, Campo E, Harris NL, et al. 2008. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. IARC Press;Lyon, France: DOI: 10.1038/315550a0.
4. Hagemeijer A. 1987; Chromosome abnormalities in CML. Baillieres Clin Haematol. 1:963–81. DOI: 10.1016/S0950-3536(87)80034-3. PMID: 3332858.
Article
5. Score J, Calasanz MJ, Ottman O, et al. 2010; Analysis of genomic breakpoints in p190 and p210 BCR-ABL indicate distinct mechanisms of formation. Leukemia. 24:1742–50. DOI: 10.1038/leu.2010.174. PMID: 20703256.
Article
6. Kang ZJ, Liu YF, Xu LZ, et al. 2016; The Philadelphia chromosome in leukemogenesis. Chin J Cancer. 35:48. DOI: 10.1186/s40880-016-0108-0. PMID: 27233483. PMCID: PMC4896164.
Article
7. Pane F, Frigeri F, Sindona M, et al. 1996; Neutrophilic-chronic myeloid leukemia: a distinct disease with a specific molecular marker (BCR/ABL with C3/A2 junction). Blood. 88:2410–4. DOI: 10.1182/blood.V88.7.2410.bloodjournal8872410. PMID: 8839830.
8. Kantarjian HM, Smith TL, McCredie KB, et al. 1985; Chronic myelogenous leukemia: a multivariate analysis of the associations of patient characteristics and therapy with survival. Blood. 66:1326–35. DOI: 10.1182/blood.V66.6.1326.1326. PMID: 3864497.
Article
9. Bartram CR, de Klein A, Hagemeijer A, et al. 1983; Translocation of c-ab1 oncogene correlates with the presence of a Philadelphia chromosome in chronic myelocytic leukaemia. Nature. 306:77–80. DOI: 10.1038/306277a0. PMID: 6580527.
10. Kantarjian HM, Keating MJ, Walters RS, et al. 1986; Clinical and prognostic features of Philadelphia chromosome-negative chronic myelogenous leukemia. Cancer. 58:2023–30. DOI: 10.1002/1097-0142(19861101)58:9<2023::AID-CNCR2820580912>3.0.CO;2-H. PMID: 3463397.
Article
11. Haferlach T, Bacher U, Kern W, Schnittger S, Haferlach C. 2008; The diagnosis of BCR/ABL-negative chronic myeloproliferative diseases (CMPD): a comprehensive approach based on morphology, cytogenetics, and molecular markers. Ann Hematol. 87:1–10. DOI: 10.1007/s00277-007-0403-6. PMID: 17938925. PMCID: PMC2082654.
Article
12. Kralovics R, Passamonti F, Buser AS, et al. 2005; A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 352:1779–90. DOI: 10.1056/NEJMoa051113. PMID: 15858187.
Article
13. Tefferi A, Lasho TL, Gilliland G. 2005; JAK2 mutations in myelo-proliferative disorders. N Engl J Med. 353:1416–7. author reply 1416–7. DOI: 10.1056/NEJMc051878. PMID: 16192494.
14. Tefferi A, Thiele J, Orazi A, et al. 2007; Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood. 110:1092–7. DOI: 10.1182/blood-2007-04-083501. PMID: 17488875.
Article
15. Böhm J, Kock S, Schaefer HE, Fisch P. 2003; Evidence of clonality in chronic neutrophilic leukaemia. J Clin Pathol. 56:292–5. DOI: 10.1136/jcp.56.4.292. PMID: 12663642. PMCID: PMC1769920.
Article
16. Jaffe ES, Harris NL, Stein H, Vardiman JW. 2001. Pathology and genetics of tumours of haematopoietic and lymphoid tissues. WHO classification of tumours. 3rd ed. IARC Press;Lyon, France: DOI: 10.3410/f.1087119.540101.
17. Saglio G, Guerrasio A, Rosso C, et al. 1990; New type of Bcr/Abl junction in Philadelphia chromosome-positive chronic myelogenous leukemia. Blood. 76:1819–24. DOI: 10.1182/blood.V76.9.1819.1819. PMID: 2224129.
Article
18. You W, Weisbrot IM. 1979; Chronic neutrophilic leukemia. Report of two cases and review of the literature. Am J Clin Pathol. 2:233–42. DOI: 10.1093/ajcp/72.2.233. PMID: 289288.
Article
19. Verstovsek S, Lin H, Kantarjian H, et al. 2002; Neutrophilic-chronic myeloid leukemia: low levels of p230 BCR/ABL mRNA and undetectable BCR/ABL protein may predict an indolent course. Cancer. 94:2416–25. DOI: 10.1002/cncr.10490. PMID: 12015767.
20. Maxson JE, Tyner JW. 2017; Genomics of chronic neutrophilic leukemia. Blood. 129:715–22. DOI: 10.1182/blood-2016-10-695981. PMID: 28028025. PMCID: PMC5301820.
Article
21. Vandenberghe P, Wlodarska I, Michaux L, et al. 2004; Clinical and molecular features of FIP1L1-PDFGRA (+) chronic eosinophilic leukemias. Leukemia. 18:734–42. DOI: 10.1038/sj.leu.2403313. PMID: 14973504.
Article
22. Gotlib J. 2017; World Health Organization-defined eosinophilic disorders: 2017 update on diagnosis, risk stratification, and management. Am J Hematol. 92:1243–59. DOI: 10.1002/ajh.24880. PMID: 29044676.
Article
23. Bain BJ, Gilliland DG, Horny HP, Vardiman JW. 2008; Chronic eosinophilic leukemia, not otherwise specified. In: Swerdlow SH, Campo E, Harris NL, et al, eds.WHO classification of tumours of haematopoietic and lymphoid tissues. WHO classification of tumours. 4th ed. Lyon, France:. IARC Press,. 51–3.
24. Murray NP. 2015; Chronic eosinophilic leukemia: a mini-review. J Hematol Blood Transfus Disord. 2:100004. DOI: 10.24966/HBTD-2999/100004.
25. Pardanani A, Brockman SR, Paternoster SF, et al. 2004; FIP1L1-PDGFRA fusion: prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia. Blood. 104:3038–45. DOI: 10.1182/blood-2004-03-0787. PMID: 15284118.
Article
26. Metzgeroth G, Erben P, Martin H, et al. 2012; Limited clinical activity of nilotinib and sorafenib in FIP1L1-PDGFRA positive chronic eosinophilic leukemia with imatinib-resistant T674I mutation. Leukemia. 26:162–4. DOI: 10.1038/leu.2011.181. PMID: 21818111.
Article
27. Oliver JW, Deol I, Morgan DL, Tonk VS. 1998; Chronic eosinophilic leukemia and hypereosinophilic syndromes. Proposal for classification, literature review, and report of a case with a unique chromosomal abnormality. Cancer Genet Cytogenet. 107:11–7. DOI: 10.1016/S0165-4608(98)00099-5. PMID: 9844604.
28. Ma SK, Kwong YL, Shek TW, et al. 1999; The role of trisomy 8 in the pathogenesis of chronic eosinophilic leukemia. Hum Pathol. 30:864–8. DOI: 10.1016/S0046-8177(99)90149-1. PMID: 10414507.
Article
29. Saitoh T, Saiki M, Inoue M, et al. 2002; CD25 positive chronic eosinophilic leukemia with myelofibrosis. Rinsho Ketsueki. 3:918–23. PMID: 12462027.
30. Lepretre S, Jardin F, Buchonnet G, et al. 2002; Eosinophilic leukemia associated with t(2;5)(p23;q31). Cancer Genet Cytogenet. 33:164–7. DOI: 10.1016/S0165-4608(01)00590-8. PMID: 11943346.
Article
31. Granjo E, Lima M, Lopes JM, et al. 2002; Chronic eosinophilic leukaemia presenting with erythroderma, mild eosinophilia and hyper-IgE: clinical, immunological and cytogenetic features and therapeutic approach. A case report. Acta Haematol. 107:108–12. DOI: 10.1159/000046640. PMID: 11919392.
Article
32. Patnaik MM, Padron E, LaBorde RR, et al. 2013; Mayo prognostic model for WHO-defined chronic myelomonocytic leukemia: ASXL1 and spliceosome component mutations and outcomes. Leukemia. 27:1504–10. DOI: 10.1038/leu.2013.88. PMID: 23531518.
Article
33. Arber DA, Orazi A, Hasserjian R, et al. 2016; The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 127:2391–405. DOI: 10.1182/blood-2016-03-643544. PMID: 27069254.
Article
34. Harris NL, Jaffe ES, Diebold J, et al. 1999; World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol. 17:3835–49. DOI: 10.1200/JCO.1999.17.12.3835. PMID: 10577857.
Article
35. Vardiman JW, Pierre R, Bain B, et al. 2001; WHO histological classification of myelodysplastic/myeloproliferative diseases. In: Jaffe ES, Harris NL, Stein H, Vardiman JW. Pathology and genetics of tumours of haematopoietic and lymphoid tissues. Lyon, France:. IARC Press,. 47–59.
36. Patnaik MM, Parikh SA, Hanson CA, Tefferi A. 2014; Chronic myelomonocytic leukaemia: a concise clinical and patho-physiological review. Br J Haematol. 165:273–86. DOI: 10.1111/bjh.12756. PMID: 24467717.
Article
37. Jankowska AM, Makishima H, Tiu RV, et al. 2011; Mutational spectrum analysis of chronic myelomonocytic leukemia includes genes associated with epigenetic regulation: UTX, EZH2, and DNMT3A. Blood. 118:3932–41. DOI: 10.1182/blood-2010-10-311019. PMID: 21828135. PMCID: PMC3193268.
Article
38. Smith AE, Mohamedali AM, Kulasekararaj A, et al. 2010; Next- eneration sequencing of the TET2 gene in 355 MDS and CMML patients reveals low-abundance mutant clones with early origins, but indicates no definite prognostic value. Blood. 116:923–32. DOI: 10.1182/blood-2010-03-274704. PMID: 20693430.
39. Itzykson R, Kosmider O, Renneville A, et al. 2013; Clonal architecture of chronic myelomonocytic leukemias. Blood. 121:2186–98. DOI: 10.1182/blood-2012-06-440347. PMID: 23319568.
Article
40. Niemeyer CM, Arico M, Basso G, et al. 1997; Chronic myelomonocytic leukemia in childhood: a retrospective analysis of 110 cases. European Working Group on Myelodysplastic Syndromes in Childhood (EWOG-MDS). Blood. 89:3534–43. PMID: 9160658.
41. Aricò M, Biondi A, Pui CH. 1997; Juvenile myelomonocytic leukemia. Blood. 90:479–88. DOI: 10.1182/blood.V90.2.479. PMID: 9226148. PMCID: PMC9120833.
Article
42. Orazi A, Germing U. 2008; The myelodysplastic/myeloproliferative neoplasms: myeloproliferative diseases with dysplastic features. Leukemia. 22:1308–19. DOI: 10.1038/leu.2008.119. PMID: 18480833.
Article
43. Emanuel PD. 1999; Myelodysplasia and myeloproliferative disorders in childhood: an update. Br J Haematol. 105:852–63. DOI: 10.1111/j.1365-2141.1999.01435.x. PMID: 10554793.
Article
44. Hasle H, Niemeyer CM, Chessells JM, et al. 2003; A pediatric approach to the WHO classification of myelodysplastic and myeloproliferative diseases. Leukemia. 17:277–82. DOI: 10.1038/sj.leu.2402765. PMID: 12592323.
Article
45. Niemeyer CM, Locatelli F. 2006; Chronic myeloproliferative disorders. In: Pui CH. Childhood leukemias. New York, NY:. Cambridge University Press,. 571–98. DOI: 10.1017/CBO9780511471001.023. PMID: 17140547.
46. Emanuel PD, Bates LJ, Castleberry RP, Gualtieri RJ, Zuckerman KS. 1991; Selective hypersensitivity to granulocyte-macrophage colony-stimulating factor by juvenile chronic myeloid leukemia hematopoietic progenitors. Blood. 77:925–9. DOI: 10.1182/blood.V77.5.925.925. PMID: 1704804.
Article
47. Pinkel D. 1998; Differentiating juvenile myelomonocytic leukemia from infectious disease. Blood. 91:365–7. DOI: 10.1182/blood.V91.1.365. PMID: 9414312.
Article
48. Tartaglia M, Niemeyer CM, Fragale A, et al. 2003; Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia. Nat Genet. 4:148–50. DOI: 10.1038/ng1156. PMID: 12717436.
Article
49. Caye A, Strullu M, Guidez F, et al. 2015; Juvenile myelomonocytic leukemia displays mutations in components of the RAS pathway and the PRC2 network. Nat Genet. 47:1334–40. DOI: 10.1038/ng.3420. PMID: 26457648.
Article
50. Stieglitz E, Taylor-Weiner AN, Chang TY, et al. 2015; The genomic landscape of juvenile myelomonocytic leukemia. Nat Genet. 47:1326–33. DOI: 10.1038/ng.3400. PMID: 26457647. PMCID: PMC4626387.
51. Sakaguchi H, Okuno Y, Muramatsu H, et al. 2013; Exome sequencing identifies secondary mutations of SETBP1 and JAK3 in juvenile myelomonocytic leukemia. Nat Genet. 45:937–41. DOI: 10.1038/ng.2698. PMID: 23832011.
Article
52. Flotho C, Kratz CP, Bergsträsser E, et al. 2008; Genotype-phenotype correlation in cases of juvenile myelomonocytic leukemia with clonal RAS mutations. Blood. 111:966–7. DOI: 10.1182/blood-2007-09-111831. PMID: 18182584.
Article
53. Matsuda K, Shimada A, Yoshida N, et al. 2007; Spontaneous improve-ment of hematologic abnormalities in patients having juvenile myelomonocytic leukemia with specific RAS mutations. Blood. 109:5477–80. DOI: 10.1182/blood-2006-09-046649. PMID: 17332249.
Article
54. Locatelli F, Niemeyer CM. 2015; How I treat juvenile myelomonocytic leukemia. Blood. 125:1083–90. DOI: 10.1182/blood-2014-08-550483. PMID: 25564399.
Article
55. Tefferi A. 2016; Primary myelofibrosis: 2017 update on diagnosis, risk- tratification, and management. Am J Hematol. 91:1262–71. DOI: 10.1002/ajh.24592. PMID: 27870387.
Full Text Links
  • BR
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr